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Abstract
Background: Immunocytochemistry and RT-PCR have been widely used for the detection of
circulating tumor cells in patients with breast cancer but their specificity is limited. Our purpose is
to utilize a convenient and specific technology to detect circulating tumor cells in breast cancer
patients.
Methods: To determine the sensitivity and specificity of our method, A431 cells were serially
diluted with human peripheral blood leukocytes and stained with CK19. A total of 73 blood
specimens including 25 healthy volunteers and 48 patients with breast carcinoma and benign tumor
were tested by flow cytometry to quantify the expression of CK19.
Results: The detectable upper limit of A431 cells was 1 cancer cell among 104 human white blood
cells. CK19 was detected in 27% of breast cancer patients but none control gives positive result.
The number of cancer cells increased gradually along with the disease stages for it was the least in
stage I (0%) and the most in stage IV (1.29%). Fifteen patients were observed during three month
chemotherapy after surgery, and most of their CK19 expression levels declined after treatment.
Conclusion: Our research convinces that the detection of CK19 in peripheral blood by flow
cytometry is also a specific and feasible method to monitor circulating tumor cells in breast cancer.
Background
Nowadays breast cancer is becoming the second leading
cause of cancer deaths in females, almost 10% women
have the risk of developing breast cancer [1]. Although
great improvements have been made in curing breast can-
cer, the overall five-year survival rate remains < 50% and
many patients relapse after surgical resection because of
the dispersion of undetectable cancer cells [2,3]. There-
fore, it is necessary to establish sensitive and specific tech-
niques for the detection of occult tumor cells. A better
method for early diagnosis may help in predicting recur-
rence and planning appropriate therapies to improve sur-
vival [4,5].
Many investigations have indicated that epithelial cells
from the initial tumor can be recognized in peripheral
blood or bone marrow aspirates of patients with breast
cancer [6,7]. The detection of circulating tumor cells
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(CTCs) in the peripheral blood of cancer patients has
been associated with recurrence and metastasis of breast
cancer [8-10]. Cytokeratins (CKs), characteristic interme-
diate filament of epithelial cells, especially CK19, are
widely used to detect tumor cells derived from epithelial
tissues [11,12]. CK19 has been shown to correlate with
poor clinical outcome for patients with breast cancer [13].
Flow cytometry is a technology which can not only give
information of high statistical precision and subpopula-
tion quantification but also analyze cells individually and
rapidly, compared with immunocytochemistry [14,15]
and reverse transcriptase polymerase chain reaction (RT-
PCR) [16,17]. In this study, flow cytometry was used to
detect occult tumor cells in peripheral blood of patients
with breast cancer. The detection of CTCs in peripheral
blood of 48 patients was intended to find the relationship
of CK19+ cell percentage with disease progress. CK19 was
positive in the peripheral white blood cells of breast can-
cer patients at stages II to IV, but not the patients at stage
I and healthy controls. The percentage of CK19+ cells was
increased following the severity of the disease and
decreased after lumpectomy and chemotherapy.
Methods
Cell line
The A431 (human epithelial carcinoma) cell line
obtained from the American Type Culture Collection was
grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 15% fetal calf serum (both from
GIBCO), 100 U/ml penicillin, and 100 μg/ml streptomy-
cin at 37°C in a humidified incubator with 5% CO2. Sub-
culture was performed when confluence reached 70%.
Patients
Breast cancer patients were treated at the Affiliated Hospi-
tal of Anhui Medical University. The cohort included 7
patients with benign tumor, 34 patients with primary
breast cancer and 7 patients with metastatic breast cancer
from October 2006 to April 2008. The patients underwent
lumpectomy except those with distant metastases. And we
detected CK19 expression of 15 patients with primary
breast cancer during three month chemotherapy. Blood
samples were obtained with informed consent after
approval of the protocol by the Ethics Committee of the
University of Science and Technology of China. Control
blood samples were collected from 25 healthy female vol-
unteers.
Blood sample preparation
The first 8 ml of blood was discarded to avoid epithelial
contamination before the collection of 5 ml blood sam-
ple. Human white blood cells were isolated from adult
peripheral blood using RBC lysis buffer (RX-2-1-2 U-gene
China). Briefly, 3 ml blood and 15 ml RBC lysis buffer
were mixed with vortex and kept on ice for 15 min until
pellucid, then were centrifuged at 450 g for 10 min. Cells
were suspended with 5 ml RBC lysis buffer and centri-
fuged at 450 g for 10 min again followed by twice rinse
with PBS.
Immunofluorescence staining
A431 cells were counted onto glass slides at a concentra-
tion of 5 × 105 cells per spot. Subsequently, the cells were
fixed with 4% paraformaldehyde in PBS for 15 min at
room temperature, rinsed in PBS, and incubated with
FITC-conjugated mouse anti-human CK19. Laser scan-
ning confocal microscopy was performed and the data
were processed with MetaMorph program.
Flow cytometric analysis
After fixation with 1% paraformaldehyde for 1 hour at
room temperature, A431 cells or leukocytes were permea-
bilized with 0.01% Triton X-100 for 1 h at room temper-
ature followed by mouse serum block (30 min, room
temperature). Then the cells were incubated with FITC-
conjugated CK19 antibody or FITC-mouse IgG1 isotype
antibody (both from BD PharMingen) as negative control
overnight. After washed twice with permeabilization
buffer, samples were analyzed by FACSCalibur (Becton
Dickinson).
Statistical analysis
K Related Samples Test was used for the analysis of CK19
expression in peripheral blood of patients before and after
clinical treatment. Mann-Whitney U test was used to com-
pare CK19 expression levels in peripheral blood between
patients at stage III and stage IV. The statistical significance
was defined as values of p < 0.05.
Results
CK19 expression in A431 cells
Immunofluorescence staining was used to detect the
CK19 expression in A431 cells. The result showed that
A431 cells were CK19-immunoreactive cells and CK19
was mainly located in the cytoplasm of A431 cells (Figure
1).
The specificity and sensitivity of flow cytometry
Intracellular flow cytometric analysis indicated that all the
A431 cells expressed high level of CK19 (Figure 2A). How-
ever, healthy adult peripheral blood white blood cells had
no CK19 expression (Figure 2B) (n = 25). A431 cells were
mixed with healthy adult white blood cells at different
ratios of 1:1, 1:10, 1:102, 1:103, and 1:104 to determine
the sensitivity of flow cytometry. It showed that the per-
centages of CK19+ cells detected by flow cytometry were
consistent with the ratios of A431/white blood cells. Flow
cytometry could distinguish the very low percentage of
CK19 expressing cells, even 1 A431 cell in 104 white bloodJournal of Experimental & Clinical Cancer Research 2009, 28:57 http://www.jeccr.com/content/28/1/57
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Detection of CK19 expression in A431 cells by immunofluoresence staining Figure 1
Detection of CK19 expression in A431 cells by immunofluoresence staining. A431 cells were incubated with FITC-
conjugated CK-19 antibody (A) or FITC-mouse IgG1 (isotype control) (B) and analyzed the expression of CK19. The scale bar 
= 20 μm.
CK19 expressions in A431 cells (A) and human white blood cells (B) Figure 2
CK19 expressions in A431 cells (A) and human white blood cells (B). The cells were fixed, permeabilized with 0.01% 
Triton X-100, stained with FITC-conjugated mouse anti-human CK19 antibody or FITC-conjugated mouse IgG1 and analyzed 
by flow cytometry.Journal of Experimental & Clinical Cancer Research 2009, 28:57 http://www.jeccr.com/content/28/1/57
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cells. It suggested that flow cytometry had specificity and
sensitivity to examine CK19 expression and possessed the
potential to detect the few circulating breast cancer cells in
the whole blood samples (Figure 3).
Patient characteristics
The characteristics of 48 patients enrolled in the study are
listed in Table 1. The age range of patients was from 28 to
82 years old and the median age was 46 years old. There
were 41 patients with no evidence of metastasis in the
liver and bone and 7 patients with metastatic breast can-
cer. All the patients with breast cancer were clinically clas-
sified as stages I to IV. The patients with primary breast
cancer were performed lumpectomy followed by chemo-
therapy. Thirteen of the 48 patients (27%) were found to
have CK19+ cells in peripheral blood including 7 patients
with primary breast cancer and 6 with metastatic breast
cancer (Table 2).
Detection of circulating breast cancer cells in peripheral 
blood of patients before surgery by flow cytometry
Flow cytometric analyses showed that no CK19 was
expressed in peripheral blood of healthy control (n = 25),
benign tumor patients (n = 7) and breast cancer patients
at stage I (n = 4) (Figures 4A, B, C). But there existed
CK19+ cells in the peripheral blood samples of patients at
stages II, III, and IV (Figure 4D, E, F), with the median of
each group of 0.15% (n = 2), 0.44% (n = 5) and 1.47% (n
= 6) (Figure 5), respectively. There was significant differ-
ence in CK19 expression between patients at stage III and
stage IV (p = 0.0043).
The change of CK19 expression in 15 patients with breast 
cancer during 3 month-chemotherapy
The dynamic expressions of CK19 in peripheral blood
lymphocytes were observed in 15 patients with primary
breast cancer during 3 month-chemotherapy after
lumpectomy. The number of CK19+ cells among 105 leu-
kocytes of each patient was presented in Figure 6. For the
7 metastatic patients, there was significant difference in
CK19 expression level before and after clinical treatment
(p = 0.001). The CK19+ cell numbers were obviously
decreased after operation and chemotherapy, and there
was almost none 3 months later (Figures 6A and 6C). For
the 8 patients without CK19+ cells before surgery, no sig-
nificant difference was seen after clinical treatment (p =
1). The numbers of CK19+ cells of 6 patients were always
Expression of CK19 in A431 cells diluted with human white blood cells at different ratios Figure 3
Expression of CK19 in A431 cells diluted with human white blood cells at different ratios. A431 cells were mixed 
with healthy adult white blood cells at different ratios of 1:1 (A), 1:10 (B), 1:102 (C), 1:103 (D), and 1:104 (E). The cell mixture 
was stained with FITC-anti-CK19 antibody and detected the expression of CK19.Journal of Experimental & Clinical Cancer Research 2009, 28:57 http://www.jeccr.com/content/28/1/57
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nearly zero during 3 month-chemotherapy, but increased
in 2 patients after treatment (Figures 6B and 6D).
Discussion
The dispersion of tumor cells is one of the primary causes
of recrudescence at distant sites and of death from cancer.
So the detection of occult metastatic cells is important to
predict recurrence and improve survival. In this study, we
applied flow cytometry to examine the expression of
CK19 in the peripheral blood of breast cancer patients to
monitor CTCs.
Immunocytochemistry gives morphological detail of
tumor cells but is not sensitive and lack of methodological
standardization [18]. Although RT-PCR is able to find 1
cancer cell among 106  irrelevant cells [19], it cannot
exactly quantify the number of tumor cells according to
mRNA levels. Furthermore, its utility was limited for its
low specificity because of the false positive results which
may be explained by the phenomenon of "illegitimate
expression" [20,21].
In the present study, flow cytometry is utilized to examine
the expression of CK19 to test CTCs in 48 breast cancer
patients because most breast cancer cells but not blood
cells express CK19. Although the sensitivity of our method
is 1 cancer cell among 104 irrelevant cells, its specificity is
very high. No CK19 expression was detected in healthy
volunteers and patients with benign tumor. We consider
high specificity is more important than high degree of sen-
sitivity for clinical diagnoses because a wrong positive test
will result in unnecessary treatments that may cause
Table 1: Details of patients and CK19 expression in peripheral blood
Number of patients % Positive cases
Pathology size
< 1 cm 5 10.4 1
1–2 cm 11 22.9 3
> 2 cm 32 66.7 9
Clinical stage
Benign tumor 7 14.6 0
I4 8 . 3 0
II 23 47.9 2
III 7 14.6 5
IV 7 14.6 6
Histology
Infiltrating ductal carcinoma 39 81.3 13
Fibroadenoma 1 2 0
Struma 6 12.5 0
Intraductal breast cancer 2 4.2 0
Distant metastasis
Metastasis 7 14.6 6
Without metastasis 41 85.4 7
Note: The patient age ranged from 28 to 82 years old.Journal of Experimental & Clinical Cancer Research 2009, 28:57 http://www.jeccr.com/content/28/1/57
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injury. Our data demonstrated that 86% of stage IV
patients and 70% of stage III patients were detected CK19+
cells in the peripheral blood, which were a little higher
than that reported by Aerts J [22]; but the percentage of
patients at stages I and II was lower. This may be explained
by that the detection of protein level is more precise than
RNA level because of the false positive result of RT-PCR
also reported by others [23]. In our study the percentages
of CK19+ cells in the peripheral blood samples of patients
were increased as the illness grew worse. This result was
similar with that of Ivy Wong and his group that positive
expression level of CK19 correlates strongly with disease
stage in colorectal cancer [24]. Moreover, most patients
positive for CK19 had a tumor size of more than 2 cm. It
was also mentioned by Weihrauch that CK19 detection
rate increased with tumor size [25]. However, Xenidis N
and his colleagues found the presence of CK19 positive
Table 2: Overview of CK19+ results in volunteers, benign tumor 
patients and stage I–IV breast cancer patients
Total number Positive Detection Rate
Healthy control 25 0/25 (0%)
Benign tumor 7 0/7 (0%)
Stage I patients 4 0/4 (0%)
Stage II patients 23 2/23 (9%)
Stage III patients 7 5/7 (70%)
Stage IV patients 7 6/7 (86%)
CK19 expression in peripheral blood of healthy controls and breast tumor patients Figure 4
CK19 expression in peripheral blood of healthy controls and breast tumor patients. Peripheral white blood cells 
were isolated and stained with FITC-conjugated mouse anti-human CK19 antibody to examine CK19 expression. (A) Healthy 
volunteers; (B) Benign tumor patients; Breast cancer patients at stage I (C), stage II (D), stage III (E) and stage IV (F).Journal of Experimental & Clinical Cancer Research 2009, 28:57 http://www.jeccr.com/content/28/1/57
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cells had nothing to do with clinicopathological prognos-
tic factors [26].
After a follow-up period of three month-chemotherapy,
the number of occult tumor cells in most metastatic
patients was decreased rapidly, convincing the effect of
adjuvant chemotherapy. In another hand, this can also be
considered that most CTCs are apoptotic [27] so they van-
ished automatically. However, 2 patients with no metas-
tasis before operation had CK19 positive cells after
chemotherapy. It may be explained by that chemotherapy
may evoke the exudation of proinflammatory cytokines
which can regulate gene expression [28]. The tumor cells
of one patient vanished after durative chemotherapy, but
for the other patient they increased during this treatment.
This phenomenon indicates that some tumor cells are
sensitive to chemotherapy but others are resistant to it.
In conclusion, we have established a simple method for
the test of CTCs in peripheral blood. Despite its sensitivity
seems not as high as PCR, the specification and quantifi-
cation accuracy is encouraging. Our technique can also be
applied for bone marrow metastasis investigation. Many
groups have reported the relationship of CK19+ cells with
reduced overall survival and risk of distant relapse. The
detection of CTCs by flow cytometry in breast cancer may
monitor disease progression and be helpful in the selec-
tion of patients who have the risk of relapse after adjuvant
treatment.
The expression level of CK19 in peripheral blood of breast cancer patients is correlated with the disease stage Figure 5
The expression level of CK19 in peripheral blood of breast cancer patients is correlated with the disease stage. 
CK19 from each peripheral blood sample was detected by flow cytometry as described in methods. All the negative results 
were shown as number undetected. All 4 patients at stage I were CK19 negative. The median is marked as "---" in each group. 
Where the frequency of negative cases is > 50%, the median cannot be shown. p < 0.05 was considered significant.Journal of Experimental & Clinical Cancer Research 2009, 28:57 http://www.jeccr.com/content/28/1/57
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Conclusion
The presence of CTCs associates with clinicopathological
factors such as tumor size and disease stage. The detection
of CK19 in peripheral blood by flow cytometry is a spe-
cific and feasible method to monitor CTCs which relate to
relapse and survival.
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The CK19+ cell number in peripheral blood of 15 patients with primary cancer before surgery and after chemotherapy Figure 6
The CK19+ cell number in peripheral blood of 15 patients with primary cancer before surgery and after chem-
otherapy. All the patients underwent surgery followed immediately by chemotherapy. The CK19+ cell numbers were tested 
before surgery, 7 days after chemotherapy and 90 days after chemotherapy.(A and C) Patients with CK19 positive cells before 
surgery; (B and D) Patients without CK19 positive cells before surgery. Different symbols represent different breast cancer 
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